( NASDAQ-SMALL:ONCS )

News from OncoSec Medical Incorporated A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Jan 18, 2018, 09:15 ET OncoSec Provides Encouraging Clinical Observations Related To Triple Negative Breast Cancer Study

OncoSec Medical Incorporated ("OncoSec" or the "Company") (NASDAQ:ONCS), a company developing intratumoral cancer immunotherapies, today announced...


Jan 16, 2018, 08:00 ET OncoSec Appoints Veteran Biopharma Executive Gregory T. Mayes To Board Of Directors

OncoSec Medical Incorporated ("OncoSec" or the "Company") (NASDAQ:ONCS), a company developing intratumoral cancer immunotherapies, today announced...


Jan 03, 2018, 08:00 ET OncoSec Provides 2018 Business Outlook

OncoSec Medical Incorporated ("OncoSec" or the "Company") (NASDAQ:ONCS), a company developing intratumoral cancer immunotherapies, announced its...


Dec 14, 2017, 08:00 ET OncoSec Announces Dosing of First Patient in Registration-Directed Phase 2b Clinical Trial, PISCES/KEYNOTE-695, of ImmunoPulse® IL-12 in Combination with Pembrolizumab

OncoSec Medical Incorporated ("OncoSec" or the "Company") (NASDAQ:ONCS), a company developing intratumoral cancer immunotherapies, today announced...


Dec 05, 2017, 08:00 ET OncoSec Announces Promotion of Christopher G. Twitty, Ph.D. to Chief Scientific Officer

OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing intratumoral cancer immunotherapies, today announced the promotion of...


Nov 28, 2017, 08:00 ET OncoSec Expands Intellectual Property Estate, Announces Issuance of Patents for ImmunoPulse® Platform

OncoSec Medical Incorporated ("OncoSec" or the "Company") (NASDAQ:ONCS), a company developing intratumoral cancer immunotherapies, today announced...


Nov 13, 2017, 17:42 ET OncoSec Receives $9.3 Million Warrant Exercise

OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that...


Nov 09, 2017, 08:00 ET OncoSec Announces Preclinical Data Demonstrating Multi-Gene Expression Platform for Delivery of Multiple Cancer Immunotherapies at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2017

OncoSec Medical Incorporated ("OncoSec") (NASDAQ:ONCS), a company developing DNA-based cancer immunotherapies, will present emerging data from its...


Nov 07, 2017, 17:03 ET OncoSec Appoints Daniel J. O'Connor as Chief Executive Officer to Lead Next Stage of Growth as a Fully Integrated Late Stage Development and Commercial Company

OncoSec Medical Incorporated ("OncoSec" or "Company") (NASDAQ:ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today...


Oct 25, 2017, 16:15 ET OncoSec Announces Fourth Quarter and Year End Financial Results for Fiscal Year 2017

OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced...


Oct 25, 2017, 12:46 ET OncoSec Closes $7.1 Million Registered Direct Offering Priced At-the-Market and Announces $1.1 Million Registered Direct Offering Priced Above Market

OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced that it has...


Oct 23, 2017, 09:00 ET OncoSec Announces $7.1 Million Registered Direct Offering Priced At-the-Market

OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that...


Oct 19, 2017, 06:00 ET OncoSec Presents Positive Phase 2 Data for ImmunoPulse® IL-12 in Combination with Pembrolizumab Demonstrating a Best Overall Response Rate (BORR) of 50% in Predicted Anti-PD-1 Non-Responder Melanoma Patients

OncoSec Medical Incorporated ("OncoSec" or "Company") (NASDAQ:ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today...


Oct 13, 2017, 08:00 ET OncoSec to Host Fourth Quarter and Year End Financial Results Conference Call on October 25, 2017

OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that...


Oct 12, 2017, 08:00 ET OncoSec to Present Updated Clinical and Immune Biomarker Data from its Monotherapy and Combination Therapy Studies with ImmunoPulse® IL-12 at the 9th World Congress of Melanoma - A Joint Meeting with the Society for Melanoma Research

OncoSec Medical Incorporated ("OncoSec") (NASDAQ:ONCS), a company developing DNA-based intratumoral cancer immunotherapies, will present new...


Oct 11, 2017, 17:03 ET OncoSec Announces Acceptance of Late Breaking Abstract at Upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting 2017

OncoSec Medical Incorporated ("OncoSec") (NASDAQ:ONCS), a company developing DNA-based intratumoral cancer immunotherapies, will present updated...


Oct 10, 2017, 08:00 ET OncoSec Initiates Registration Directed Clinical Trial, KEYNOTE-695, of ImmunoPulse® IL-12 in Combination with Merck's KEYTRUDA® (pembrolizumab)

OncoSec Medical Incorporated ("OncoSec" or the "Company") (NASDAQ:ONCS), a company developing intratumoral cancer immunotherapies, today announced...


Sep 27, 2017, 08:00 ET OncoSec Presents Clinical Overview of Comprehensive Immune Monitoring Data Demonstrating Conversion of "Cold" Tumors to "Hot" Tumors with ImmunoPulse® IL-12 and Pembrolizumab Combination Therapy

OncoSec Medical Incorporated ("OncoSec") (NASDAQ:ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today presented an...


Sep 26, 2017, 16:01 ET OncoSec to Present at the Cantor Fitzgerald Global Healthcare Conference

OncoSec Medical Incorporated ("OncoSec") (NASDAQ:ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced that...


Sep 07, 2017, 06:00 ET OncoSec Appoints Industry Leader Daniel J. O'Connor to its Board of Directors

OncoSec Medical Incorporated "OncoSec" (NASDAQ:ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced the...


Sep 06, 2017, 14:44 ET OncoSec Announces Presentations at Upcoming Investment and Scientific Conferences

OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that...


Sep 05, 2017, 06:00 ET OncoSec Appoints Industry Veteran Annalisa Jenkins MBBS, FRCP to Board of Directors

OncoSec Medical Incorporated ("OncoSec" or the "Company" (NASDAQ: ONCS)), a company developing DNA-based intratumoral cancer immunotherapies, today...


Jun 12, 2017, 06:01 ET OncoSec Announces Technology Access Program Agreement with Jounce Therapeutics, Inc.

OncoSec Medical Incorporated ("OncoSec") (NASDAQ:ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced that...


Jun 08, 2017, 16:30 ET OncoSec Granted Orphan Drug Designation from the U.S. FDA for the Treatment of Unresectable Metastatic Melanoma

OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced that...